Cheryl Campbell is a cancer pharmacologist, lawyer, entrepreneur and a member of the MIT EMBA class of 2015.
One of the most significant hurdles scientists in the life sciences face in developing the next drug or device is raising capital. With several years of research and development required before the creation of a minimum viable product and another several years to market, scientists need significant funding in order to commercialize their scientific discoveries. However, given the long road to commercialization and regulatory hurdles along the way, life sciences investments are often risky, which discourages many investors from this field. Without a revenue-generating product or capital investment, how do scientists fund commercialization of their scientific discoveries?.